Free Trial
NASDAQ:BJDX

Bluejay Diagnostics 8/14/2024 Earnings Report

Bluejay Diagnostics logo
$1.60 +0.01 (+0.63%)
As of 03:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bluejay Diagnostics EPS Results

Actual EPS
-$256.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bluejay Diagnostics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bluejay Diagnostics' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Bluejay Diagnostics Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Bluejay Diagnostics Inc BJDX
Bluejay Diagnostics announces abstract acceptance at 2025 SAEM meeting
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX) is a medical technology company focused on the development and commercialization of non-invasive breath-based diagnostics. Leveraging proprietary sensor arrays and data analytics, the company’s core platform is designed to detect volatile organic compounds (VOCs) and other biomarkers in exhaled breath. This approach aims to enable rapid, point-of-care screening and monitoring for respiratory diseases, oncology indications and infectious agents without the need for blood draws or complex laboratory infrastructure.

The company’s initial product candidates are centered on a handheld breathalyzer device paired with single-use disposable cartridges that collect and analyze breath samples in real time. Bluejay Diagnostics is advancing clinical studies to validate the sensitivity and specificity of its technology for conditions such as early-stage lung cancer, chronic obstructive pulmonary disease (COPD), and select viral or bacterial respiratory infections. By integrating miniaturized sensor technology with machine learning algorithms, the platform seeks to distinguish disease signatures at low biomarker concentrations, supporting both diagnostic and triage workflows in outpatient, urgent care and hospital settings.

Founded in 2018 and headquartered in Medford, Massachusetts, Bluejay Diagnostics emerged from collaborative research programs involving academic institutions and technology incubators. Over its history, the company has secured partnerships with medical centers and research organizations in North America and Europe to conduct multi-center validation studies. This global footprint is intended to facilitate regulatory filings and market entry across diverse healthcare systems, with an emphasis on affordability and ease of use in decentralized environments.

Bluejay Diagnostics is led by a management team with deep experience in molecular diagnostics, medical device engineering and commercialization. The executive leadership includes industry veterans who have previously brought diagnostic platforms through regulatory approval and commercial launch. Supported by a board of directors and scientific advisors, the company continues to expand its pipeline and refine its breath analysis technology as it moves toward pivotal clinical trials and regulatory submissions.

View Bluejay Diagnostics Profile

More Earnings Resources from MarketBeat